Neurocrine Biosciences, Inc. (NBIX)
157.82
+1.06
(+0.68%)
USD |
NASDAQ |
Sep 02, 16:00
157.82
0.00 (0.00%)
After-Hours: 19:41
Neurocrine Biosciences Research and Development Expense (TTM) : 1.131B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.131B |
| March 31, 2026 | 1.049B |
| December 31, 2025 | 1.016B |
| September 30, 2025 | 936.90M |
| June 30, 2025 | 876.30M |
| March 31, 2025 | 816.70M |
| December 31, 2024 | 707.60M |
| September 30, 2024 | 660.80M |
| June 30, 2024 | 609.00M |
| March 31, 2024 | 565.90M |
| December 31, 2023 | 547.20M |
| September 30, 2023 | 528.70M |
| June 30, 2023 | 494.80M |
| March 31, 2023 | 485.20M |
| December 31, 2022 | 448.70M |
| September 30, 2022 | 419.00M |
| June 30, 2022 | 405.20M |
| March 31, 2022 | 345.40M |
| December 31, 2021 | 317.20M |
| September 30, 2021 | 297.30M |
| June 30, 2021 | 274.30M |
| March 31, 2021 | 280.90M |
| December 31, 2020 | 266.40M |
| September 30, 2020 | 255.11M |
| June 30, 2020 | 233.49M |
| Date | Value |
|---|---|
| March 31, 2020 | 216.37M |
| December 31, 2019 | 196.26M |
| September 30, 2019 | 182.16M |
| June 30, 2019 | 172.36M |
| March 31, 2019 | 147.66M |
| December 31, 2018 | 160.52M |
| September 30, 2018 | 147.03M |
| June 30, 2018 | 134.01M |
| March 31, 2018 | 118.89M |
| December 31, 2017 | 121.83M |
| September 30, 2017 | 118.80M |
| June 30, 2017 | 117.28M |
| March 31, 2017 | 122.27M |
| December 31, 2016 | 94.29M |
| September 30, 2016 | 93.52M |
| June 30, 2016 | 96.96M |
| March 31, 2016 | 88.82M |
| December 31, 2015 | 81.49M |
| September 30, 2015 | 75.18M |
| June 30, 2015 | 62.99M |
| March 31, 2015 | 54.43M |
| December 31, 2014 | 46.42M |
| September 30, 2014 | 39.84M |
| June 30, 2014 | 36.97M |
| March 31, 2014 | 37.34M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Amarin Corp. Plc | 16.15M |
| Liquidia Corp. | 54.95M |
| Incyte Corp. | 2.098B |
| Halozyme Therapeutics, Inc. | 102.37M |
| Iovance Biotherapeutics, Inc. | 267.71M |